More on SNTI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.46 |
|
|||
| Open | $0.44 | ||||
| 52 Wk High | $5.10 | ||||
| 52 Wk Low | $1.28 | ||||
| Day High | $0.46 | ||||
| Day Low | $0.42 | ||||
| P/E | N/A | ||||
| EPS | $-2.99 | ||||
| Volume | 408,306 | ||||
- Senti Biosciences (SNTI) files for 15.97M share offering by selling stockholders
- Senti Biosciences to spin off SENTI-202 unit in CVR deal
- Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable
- Radoff-JEC Group pushes for board change at Seer, Inc.
- The Radoff-JEC Group Releases Presentation Highlighting Why Seer, Inc. Stockholders Should Vote for Boardroom Change
- Senti Biosciences (SNTI) files for 15.97M share offering by selling stockholders
- Senti Biosciences (SNTI) Misses Q1 EPS by 14c
- Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
- Senti Bio receives FDA guidance for SENTI-202 registrational trial
- Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Update
Entities mentioned with SNTI
- Twitter | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Chardan Capital Markets | View Related Stories »
- 13G | View Related Stories »
- Show More...
